LAVA Therapeutics NV

詳細情報 LAVA Therapeutics NV 企業名

LAVA Therapeutics NV, formerly known as Lava Therapeutics BV, is a provider of biotechnology research and development services based in the Netherlands. The Company focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.

企業情報

企業コードLVTX

会社名LAVA Therapeutics NV

上場日Mar 25, 2021

最高経営責任者「CEO」Mr. Stephen A. Hurly

従業員数34

証券種類Ordinary Share

決算期末Mar 25

本社所在地Yalelaan 60

都市UTRECHT

証券取引所NASDAQ Global Select Consolidated

国Netherlands

郵便番号3584 CM

電話番号31630003035

ウェブサイトhttps://www.lavatherapeutics.com/

企業コードLVTX

上場日Mar 25, 2021

最高経営責任者「CEO」Mr. Stephen A. Hurly

役員一覧

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Hans Van Der Vliet, M.D., Ph.D.

Chief Scientific Officer

77.35K

--

Dr. Kapil Dhingra, M.D.

Non-Executive Chairman of the Board

30.00K

--

Ms. Karen J. Wilson, CPA

Non-Executive Independent Director

10.00K

--

Ms. Amy Garabedian

General Counsel, Corporate Secretary

8.85K

--

Ms. Nanna L. Lueneborg, Ph.D.

Non-Executive Director

--

Dr. Guido Magni, M.D., Ph.D.

Non-Executive Director

--

Mr. Stephen A. Hurly

President, Chief Executive Officer, Management Director

--

Mr. Joel Jean-Mairet, Ph.D.

Non-Executive Director

--

Mr. Benjamin Winograd, M.D., Ph.D.

Chief Medical Officer

--

Dr. Paul W.H.I. Parren

Executive Vice President Head of Research and Development

--

詳細を見る

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Hans Van Der Vliet, M.D., Ph.D.

Chief Scientific Officer

77.35K

--

Dr. Kapil Dhingra, M.D.

Non-Executive Chairman of the Board

30.00K

--

Ms. Karen J. Wilson, CPA

Non-Executive Independent Director

10.00K

--

Ms. Amy Garabedian

General Counsel, Corporate Secretary

8.85K

--

Ms. Nanna L. Lueneborg, Ph.D.

Non-Executive Director

--

Dr. Guido Magni, M.D., Ph.D.

Non-Executive Director

--

収益内訳

データなし

データなし

事業別

地域別

データなし

株主

更新時刻: Sat, Sep 6

株主統計

種類

株主統計

比率

Cooperatieve Gilde Healthcare IV UA

20.61%

Versant Ventures

11.04%

Redmile Group, LLC

7.89%

BML Capital Management LLC

7.49%

Sanofi SA

7.30%

他の

45.68%

株主統計

比率

Cooperatieve Gilde Healthcare IV UA

20.61%

Versant Ventures

11.04%

Redmile Group, LLC

7.89%

BML Capital Management LLC

7.49%

Sanofi SA

7.30%

他の

45.68%

種類

株主統計

比率

Corporation

32.27%

Venture Capital

11.04%

Investment Advisor

10.30%

Investment Advisor/Hedge Fund

7.94%

Individual Investor

1.28%

Hedge Fund

0.48%

Research Firm

0.23%

他の

36.46%

機関投資家保有株

更新時刻: Tue, Jul 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q2

48

18.32M

69.64%

-2.74M

2025Q1

59

22.25M

84.60%

-1.27M

2024Q4

61

18.80M

71.50%

-11.80K

2024Q3

56

15.93M

60.60%

-3.34M

2024Q2

58

16.07M

61.13%

-4.19M

2024Q1

58

16.06M

61.10%

-4.38M

2023Q4

51

18.10M

68.85%

+283.15K

2023Q3

52

18.00M

68.48%

-418.56K

2023Q2

55

18.03M

68.58%

-1.16M

2023Q1

60

19.21M

73.06%

-886.64K

詳細を見る

株主動向

会社名

保有株式数

比率

変動額

変動率

日付

Cooperatieve Gilde Healthcare IV UA

5.42M

20.61%

--

Mar 31, 2025

Versant Ventures

4.59M

17.44%

--

Mar 31, 2025

Redmile Group, LLC

2.07M

7.89%

--

Mar 31, 2025

BML Capital Management LLC

1.96M

7.45%

+2.50K

+0.13%

Mar 31, 2025

Sanofi SA

1.92M

7.3%

+1.92M

--

Dec 31, 2024

Merck & Co Inc

1.15M

4.37%

--

Mar 31, 2025

Bruce & Company, Inc.

521.87K

1.98%

-250.00K

-32.39%

Mar 31, 2025

Pathway Financial Advisors, LLC

102.50K

0.39%

--

Mar 31, 2025

Powell (Fred M)

65.00K

0.25%

-7.56K

-10.42%

Mar 31, 2025

詳細を見る

1.485USD

LAVA Therapeutics NV

1.485

概要

企業名

金融

分析